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Summary 
 
Background Generalized epilepsy with genetic etiology (GGE) is the most common type of 
inherited epilepsy characterized by absence, myoclonic and generalized tonic-clonic seizures 
typically occurring with generalized spike-and-wave discharges on electroencephalography. 
Despite a high concordance rate of 80% in monozygotic twins, the genetic background is still 
poorly understood.  
 
Methods Cases included in the study were clinically evaluated for GGE. Whole-exome 
sequencing (WES) was performed for the discovery case cohort, the first validation case cohort 
and for two independent control cohorts. A second replication case cohort underwent targeted 
next-generation sequencing of the 19 known genes encoding subunits of GABAA receptors and 
was compared to the respective GABAA receptor variants of a third independent control cohort. 
Functional investigations were performed using automated two-microelectrode voltage clamping 
in Xenopus oocytes. 
 
Findings Statistical comparison of 152 familial index cases with GGE in the discovery cohort to 
549 ethnically matched controls suggested an enrichment of rare missense variants in the ensemble 
of GABAA receptor encoding genes in cases. The enrichment for these genes could be validated 
in a second WES cohort of 357 sporadic and familial GGE cases and 1485 independent controls. 
Comparison of GABAA receptor genes in a second independent replication cohort of 635 familial 
and sporadic GGE index cases, based on candidate-gene panel sequencing, to a third independent 
control cohort confirmed the overall enrichment of rare missense variants in cases. Functional 
studies for two selected genes (GABRB2, GABRA5) showed significant loss-of-function effects 
with reduced current amplitudes in four of seven tested variants compared to wild-type receptors.  
 
Interpretation Our results suggest that functionally relevant variants in GABAA receptor subunit 
encoding genes constitute a significant risk factor for GGE. This conclusion is based on an 
enrichment of rare variants in those genes in three independent case-control datasets and 
physiological studies revealing a loss of function for tested variants which are supposed to favor a 
neuronal disinhibition which is a well-known mechanism in epilepsy. We further show that 
examining the role of specific gene groups and pathways can be used to disentangle the complex 
genetic architecture of GGE. 
 
Funding The study was supported by different national funding agencies in the frame of 
EuroEPINOMICS (a project of the European Science Foundation), by Epicure and EpiPGX 
(funded by the FP6 and FP7 programs of the European Commission), by Research Unit FOR2715 
(funded by the DFG and the FNR), and by a couple of smaller grants from different bodies. More 
detailed information on the funding sources is given in the acknowledgements. 
  
 
 
Research in context 
 
Evidence before this study 
Generalized epilepsies with genetic etiology (GGE) are a group of diseases with a complex 
inheritance, meaning that probably many common and rare genetic factors are involved in the 
etiology of the disease, the genetic architecture of which is still largely unknown. We searched the 
Pubmed database for articles published in English language with the search terms “Exome 
sequencing ion channels", "exome sequencing genetic generalized epilepsy" or "exome 
sequencing idiopathic generalized epilepsy”, until May 30, 2017.". At the time we conducted this 
study, there were only two studies which had performed targeted or whole-exome sequencing in 
smaller cohorts of subjects with GGE. Neither study detected significant differences in the burden 
of rare genetic variants in cases vs. controls. One study used a targeted Sanger sequencing 
approach in 237 ion channel genes in 152 cases vs. 139 normal controls. The other study applied 
whole exome sequencing to 118 subjects with juvenile myoclonic epilepsy and absence epilepsy, 
two of the main sub-phenotypes of GGE, and 242 controls. In a recent third study by the Epi4K 
and EP/GP consortia whole exomes of 640 subjects with GGE and 3877 controls were sequenced 
which showed that the rate of ultra-rare deleterious variants in a group of established epilepsy 
genes was significantly increased; no single gene showed a mutational burden in GGE.  
 
Added value of this study 
We have detected a difference between cases and controls in missense variants in a specific group 
of genes encoding all known GABAA receptors. This finding is novel in the literature. We were 
able to reproduce this signal in two independent cohorts of cases in comparison to two independent 
control cohorts. We also demonstrate the functional relevance of some of the detected variants in 
two GABAA receptor subunit genes that were so far not known to be associated with GGE or 
epilepsy. Our study therefore provides strong evidence that variation in GABAA receptor encoding 
genes confers a genetic burden in GGE. It also points at the utility of burden analysis of sets of 
genes involved in specific physiological pathways in explaining the genetics behind the 
generalized epilepsies. 
 
Implications of all the available evidence 
The study by the Epi4K and EPGP consortia and our findings present the first evidence of a 
significant genetic burden in GGE compared to controls in ultra-rare variants affecting previously 
identified epilepsy genes or as suggested here in the specific gene group of the most important 
inhibitory receptors in the mammalian brain.  
 
Introduction 
  
Gene discovery in monogenetic diseases, including familial and severe epilepsy syndromes, has 
revealed a steadily increasing number of disease-causing genetic defects. Unraveling the genetic 
architecture of complex disorders has been more difficult. GGE comprises common epilepsies 
with generalized absence, myoclonic and tonic-clonic seizures1. Its high heritability, as has been 
shown in twin studies2. A few single nucleotide polymorphisms in genome-wide association 
studies and altered copy number variations have been the major common risk factors identified so 
far in GGE. These, however, only explain a small part of the high heritability. Single gene defects 
in larger families with autosomal dominantly inherited GGE have been identified as disease-
causing, e.g. in GABRA1 or GABRG2 encoding subunits of GABAA receptors3–5, or in SLC2A1 
encoding the glucose transporter type 16,7. Early sequencing-based candidate-gene or whole-
exome sequencing (WES) studies did not reveal a significant burden of mutations in single genes 
or groups of genes thus far8,9. A recent study has demonstrated mutational burden of ultra-rare 
variants in gene-sets related to epilepsy10. 
We set out to investigate the burden of rare genetic variants in familial GGE by first testing all 
genes in a hypothesis-free approach, and second hypothesis-driven disease-relevant gene-sets. 
Significant findings were validated and replicated in additional cohorts and functional studies 
performed for selected variants. Our results indicate a genetic burden in GGE across a gene-set 
encoding all GABAA receptor subunits. 
 
Methods 
Participants 
GGE diagnoses in this study were based on clinical grounds, i.e. on clinical interview, neurological 
examination, EEG recordings and available imaging data, by experienced epileptologists 
according to ILAE classifications at the time of diagnosis and recruitment. All patients fulfill the 
criteria of the latest version from 20171. Written informed consent was obtained from all subjects 
or their relatives. The study was approved by local Ethical Committees. One affected individual 
of each family was selected for sequencing. 
We used three different GGE case cohorts and three independent control cohorts, all of European 
descent, for our sequencing studies. The GGE diagnoses included mainly the classical four 
phenotypes of childhood or juvenile absence epilepsy (CAE, JAE), juvenile myoclonic epilepsy 
(JME), or GGE with generalized tonic-clonic seizures alone (EGTC); we included few cases with 
early-onset absence epilepsy (EOAE, defined as beginning below three years of age), epilepsy 
with myoclonic absences (EMA) and up to 30% unclassified GGE, since these entities in our view 
are close to classical GGE. For EOAE it has been recently suggested by a large study that it is 
likely genetically similar to classical CAE11, EMA may also have genetic overlaps with GGE12 
and we often find in family studies both well classified and unclassified GGE cases in the same 
  
pedigrees (see appendix for detailed phenotypes in all cohorts). The first, discovery WES case 
cohort included 152 subjects (after quality control (QC)) with GGE from multiplex families, 
collected by the Epicure and the EuroEPINOMICS-CoGIE consortia. The majority of cases 
(n=143, 94%) derived from multiplex families with at least two affected family members, thereof 
76 families with three or more affected members (table S1). The second, validation cohort 
consisted of 357 GGE cases (after QC) collected by the EpiPGX consortium. 92 cases (26%) 
derived from families with at least two affected members. 131 cases were sporadic, for the 
remaining 134 cases, familial history was not known (table S2). Two independent WES control 
cohorts were obtained from two separately sequenced cohorts (termed A and B) from the 
Rotterdam study13,14 which were matched for ethnicity (see appendix). All controls were at least 
55 years old or older and checked for several neurological conditions at baseline. As GGE is a 
disease with typical onset from childhood to adolescence, it is unlikely that people at this age could 
still develop GGE. Controls were chosen so that the distribution of sexes was similar to according 
cases. The third, replication cohort, was collected in Quebec, Canada, and in Europe for GABAA 
receptor gene panel sequencing (table S3). 154 cases (24%) were familial with at least 2 affected 
family members, for 51 there was a positive family history of epilepsy, and 426 cases were 
sporadic. A third independent set of controls (cohort C) was obtained from the UK10K project 
consortium15 (see appendix 4c). UK10K control samples were of self-reported European ethnicity 
and were processed to remove outlier samples (figures S6 and S7). A total of 639 ethnically 
matched individuals were selected from the control cohort C. 
Procedures 
For the discovery stage, paired-end WES of cases and controls (set A and B) was performed with 
the Illumina HiSeq 2000 using the EZ Human Exome Library v2.0 kit (NimbleGen, Madison, WI). 
Cases and controls were sequenced at different locations, cases at the Cologne Center for 
Genomics and the control cohort A in Rotterdam13. Sequencing adapters were trimmed and 
samples with <30X mean depth or <70% total exome coverage at 20X mean depth of coverage 
were excluded from further analysis. For the validation cohort, WES was performed at deCODE 
genetics (Iceland) on the Illumina HiSeq 2500 using the Nextera Rapid Capture Expanded Exome 
kit (Illumina). The Rotterdam control set B14 was sequenced as set A. Variant calling was 
performed by using the GATK16 best practices pipeline with the GRCh37 human reference genome 
(see appendix). To exclude low quality variants, we performed an additional filtering based on 
quality metrics of individual genotypes, using read depth and genotype quality as the filtering 
criteria. We excluded any variant position with mean depth of <10 in either cases or controls. For 
all WES samples, the same exome regions file from the EZ Human Exome Library v2.0 kit was 
used. Only samples with more than 30X mean coverage or more than 70% of the exome intervals 
covered by at least 20x mean coverage were included for analysis (appendix).  
  
For the replication cohort, a total of 19 genes encoding known subunits of GABAA receptors were 
selected for deep sequencing (appendix). After quality trimming, sequencing reads were mapped 
against the GRCh37 human reference genome using the GATK16 suite and the MUGQIC pipelines 
(https://bitbucket.org/mugqic/mugqic_pipelines). Data from the control cohort C were processed 
using the same pipelines as the cases. Coverage comparisons were made to keep bases covered in 
at least 95% of the subjects as well as the control cohort.  
RefSeq gene annotation information was used for the classification into missense and synonymous 
variants and to filter for rare (allele frequency smaller than 0.5%) variants using the ExAC 
database17 (appendix).  
Population stratification 
For both WES datasets, selected common variants from each study were chosen and principal-
components analysis (PCA) was applied to assess potential population substructure separately for 
each case-control cohort, using the implementation in Eigenstrat18. Population outliers were 
defined as SD of >3 based on the first 10 PC and excluded from further analysis (appendix).  
Statistical analysis 
Due to the limited sample size, single-gene collapsing analysis for the discovery stage was 
performed using Combined and Multivariate Collapsing19(CMC) method with a two-sided Fisher's 
exact test, as implemented in the Exact CMC method in rvtests20 (appendix). P-values for single-
gene collapsing tests were corrected for multiple testing by use of the Bonferroni method for 
18,668 protein-coding genes.  
 
For all three stages, gene-set collapsing tests were performed using the regression-based two-sided 
SKAT-O method21, as implemented in rvtests20. For the two WES cohorts, we included sex and 
the first 10 PC from the Eigenstrat analysis as covariates to account for possible gender and 
population substructure effects. Gene-set collapsing tests were applied separately to missense and 
to synonymous variants. Three disease-related and four process-specific gene-sets related to GGE 
were constructed (appendix table S5). To control the family-wise error rate, we applied Holm’s 
correction for multiple testing 14 hypotheses (seven gene-sets for missense and synonymous 
variants each), in the discovery cohort, while correction was done for only two hypotheses in both 
the validation and the replication cohort, since only the GABAA receptor gene-set was carried 
forward (appendix). The odds ratio (OR) for a given gene-set was determined by comparing the 
presence of qualifying rare (nonsynonymous or synonymous) variants in all genes within each 
gene-set between cases and controls using the R package 'fmsb'. 
 
Functional analysis 
  
Functional experiments were performed using automated two-microelectrode voltage clamping in 
Xenopus oocytes. All methods for functional studies have been described previously21,22 
(appendix).  
Role of the funding source  
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation or writing. The authors had full access to the data in the study and had final 
responsibility for the decision to submit for publication. 
Results 
We first performed WES in a discovery cohort of 238 independent, mainly familial cases of 
classical forms of GGE (CAE/JAE, JME or EGTCA). As controls, we used the ethnically matched 
(figure S1) population control cohort A from the Rotterdam study13, that used the same enrichment 
and sequencing procedures, albeit with a somewhat lower coverage. After quality control (QC) 
and population outlier removal, the final dataset consisted of 152 unrelated GGE and 549 control 
samples. To adjust for the different coverage, we considered only variants with an average read 
depth of >10 both in case and control samples (figure S2). From 701 samples, 204,023 exonic and 
splice site variants were called. The mean exonic transition/transversion ratio equaled 3.46, 
indicating good data quality. Rare variants (MAF<0.005) were classified as missense (Nonsyn) 
and silent (Syn) variants. 93,893 Nonsyn and 55,170 Syn variants constituted the analysis data set 
(see appendix, table S4). When testing hypothesis-free all RefSeq genes separately for association, 
we could not identify genes enriched for any variant type (appendix). Therefore, we next applied 
an independent hypothesis-driven analysis by testing the enrichment of rare variants in seven gene-
sets related to epilepsy or underlying molecular processes, representing (i) all voltage-gated cation 
channels, (ii) all excitatory postsynaptic receptors, (iii) all GABAA receptors as the main inhibitory 
postsynaptic receptors, (iv) more broadly the GABAergic pathway (since such genes have been 
associated specifically with generalized epilepsies), and genes associated (v) with generalized 
epilepsies, (vi) epileptic encephalopathies, or (vii) focal epilepsies (appendix table S4). We tested 
separately for each variant type; silent variants were expected to show no difference between cases 
and controls. We found an enrichment for missense variants in the GABAA receptor gene-set 
which was significant when correcting for multiple comparisons in the seven gene-sets for both 
Nonsyn and Syn (so 14 altogether) by use of the two-sided SKAT-O test (19 genes, pNonsyn=0.0014, 
adjusted p*Nonsyn=0.019, OR=2.40, 95% CI=[1.41,4.10]) (table 1). However, the GABAA receptor 
gene-set would not have reached study-wide significance when also correcting for all single genes 
tested before. None of the other gene-sets showed a significantly increased burden of rare variants. 
Synonymous variants, used as a negative control, did not show a significant enrichment in any of 
the gene-sets (tables 1 and S8). 
 
  
To validate the finding for the GABAA receptor encoding genes, we used the second, validation 
cohort, consisting of 724 individuals with GGE from six European countries. They were mainly 
sporadic (n=268, 37%) or of unknown familial history (n=265, 37%) and diagnosed with classical 
forms of GGE (table S2). For comparison, control cohort B from the Rotterdam study14 was used. 
After applying the same QC steps as for the discovery stage, the dataset consisted of 357 unrelated 
GGE and 1485 control samples. Consistent with the discovery stage, we observed a significant 
enrichment of rare missense variants in the GABAA receptor gene-set in cases after multiple-
testing correction for two sets of variants (Nonsyn, Syn; pNonsyn=0.0081, adjusted p*Nonsyn=0.016, 
OR=1.46, 95% CI=[1.05,2.03]) using the SKAT-O test (table 1 and S8). Synonymous variants 
showed no significant enrichment. 
 
For a third, independent replication cohort, consisting of 631 cases with familial or sporadic GGE 
(table S3), we designed a targeted enrichment panel comprising all 19 GABAA receptor encoding 
genes. GABRR3 was excluded for QC reasons. Since no genotype data for the cases were available 
and therefore gender QC could not be performed, the burden analysis was restricted to the 
remaining 15 autosomal GABAA receptor genes. We obtained control samples from the UK10K 
project (https://www.uk10k.org/) and selected 639 individuals after sample QC. Additional variant 
QC led to a final dataset of 583 unrelated cases and 635 controls. We replicated a significant 
enrichment of rare missense variants for 15 GABAA receptor genes in cases compared to controls 
(pNonsyn=0.013, adjusted p*Nonsyn=0.027, OR=1.46, 95% CI=[1.02,2.08], table 1) by use of a 
SKAT-O test. Synonymous variants were not significantly enriched.  
 
We thus conclude that enrichment of rare missense variants in GABAA receptor encoding genes is 
reproducibly present in individuals with GGE compared to controls. All detected case-only 
variants are provided in tables S8 and S9. Case-only rare missense variants were found across all 
GABAA receptor genes except in GABRR3 (table S8).  
 
The combination of two α1-, two E2- and one γ2-subunit (genes GABRA1, GABRB2, GABRG2) 
represents the most common form of a functional GABAA receptor in the brain24, and variants in 
GABRA1 and GABRG2 have been shown to play an important role in familial GGE, febrile seizures 
and EE4,5,22,23,25–27. Importantly, the observed enrichment of missense variants was not driven by 
variants in those two epilepsy genes; the signal was no longer significant when reducing the 
analysis to those two genes (table S9). Instead, the qualifying variants were evenly distributed over 
all GABAA receptor encoding genes. The α5 subunit (gene GABRA5) is supposed to mediate 
extrasynaptic tonic inhibition28, and tonic inhibition has been described to be altered in genetic 
mouse models of epilepsy29,30. GABRB2 and GABRA5 have not previously been associated with 
GGE, although GABRB2 mutations were described recently in patients with intellectual disability 
and epilepsy31–33. 
 
  
For functional studies, we therefore selected seven missense variants in GABRB2 and GABRA5 
(appendix, point 6 and table S10) identified in GGE families for electrophysiological studies in 
Xenopus oocytes. All selected variants were confirmed by Sanger sequencing. Five of these 
variants were selected since they co-segregated with the phenotype in nuclear families. Another 
variant (p.R3S) was found in three different French-Canadian pedigrees, so we hypothesized that 
this could be a more common causal variant in a specific population (figures 1a and 2a). The last 
variant, p.P453L, did not co-segregate, but was selected as additional GABRA5 variant localized 
in a different protein region (the C-terminus) than the other variants. All missense variants were 
predicted to be deleterious by at least three out of seven prediction tools and were highly conserved 
(table S9). Three of these variants were consistently of ultra-low frequency in the European 
population in different public databases (1000G, ExAC, gnomAD; table S9). Localization of the 
variants is shown in figures 1b and 2b.  
 
After application of 1 mM GABA, we observed a significant reduction in current amplitudes of 
GABAA receptors containing either p.K221R or p.V316I variants in the β2-subunit, and p.M1I or 
p.S238N in the α5-subunit, in comparison to respective compositions of WT receptors. No 
significant reductions were observed for p.R3S in the β2- and for p.E243K or p.P453L in the α5-
subunit (figures 1c, 1d, 2c, 2d). The GABA sensitivity was similar for WT and all of the variant-
carrying receptors (figures 1e, 2e). Thus, four out of seven variants lead to a loss of receptor 
function predicting postsynaptic or extrasynaptic neuronal disinhibition.  
 
All four variants inducing significantly reduced current amplitudes co-segregated with the disease 
phenotype in respective pedigrees (figures 1a, 2a), corroborating their pathophysiological 
contribution. In two families, we observed co-segregating variants in two different GABAA 
receptor subunits: p.V316I in the β2- and p.M1I in the α5-subunit co-occurred in the same nuclear 
family, and p.E243K in the α5-subunit was accompanied by a deleterious frameshift mutation in 
GABRG2 in another family (figures 1a, 2a). We did not see a significant change in GABA-evoked 
currents for p.E243K, suggesting that GABRG2 may be a dominant disease-contributing gene in 
this family. However, as GGE only occurs in individuals carrying variants in both genes, we cannot 
exclude that p.E243K contributes to the phenotype with a more subtle functional change that could 
not be detected in our assay. Variants with altered receptor function were all located in the N-
terminus containing GABA-binding sites or in the pore region. p.M1I suppresses the start codon 
such that translation starts six amino acids later, which shortens the signalling peptide consisting 
of the first 20 amino acids. While the peptide is removed and not part of the mature GABAA 
receptor in the plasma membrane, this alteration could still affect protein biogenesis leading to 
reduced expression of functional receptors. p.R3S, which also affects the signalling peptide, and 
p.P453L, located in the functionally less relevant C-terminus, did not lead to a significant change 
in receptor function. p.R3S recurred in three French-Canadian families and p.P453L was detected 
  
in only one of several affected members of a larger family indicating that they might represent 
benign polymorphisms. 
 
Discussion 
We report an enrichment of rare missense variants in GABAA receptor subunit encoding genes in 
three independent cohorts which together comprise >1000 GGE index cases (both familial and 
sporadic). Four selected variants in two genes (GABRB2, GABRA5) previously not associated with 
GGE changed receptor function and co-segregated in nuclear families, suggesting an important 
contribution to the GGE phenotype. Previous studies in smaller cohorts failed to show a significant 
excess of variants in cases versus controls either investigating all ion channel encoding genes8 or 
using single-gene collapsing tests based on whole exomes9. The difference between these previous 
studies and ours could be explained by (i) a larger sample size in our study across all cohorts and 
(ii) by testing different gene-sets that had not been considered before. In a recent study10, a similar 
effect could be shown for ultra-rare deleterious variants in gene-sets comprising known epilepsy 
genes or genes associated with epileptic encephalopathies (GABAA receptor genes were not 
investigated as a separate gene-set). Due to our smaller sample size and the associated low number 
of ultra-rare variants, we here chose a different approach considering all variants with a 
MAF<0.5%, which revealed significant genetic signals in studies of other diseases34–36. Both 
studies (i.e. Epi4k and ours) failed to identify single genes with a genome-wide significant burden 
of rare variants in individuals with GGE. It will be interesting in future studies to combine different 
cohorts to increase power for such analyses and shed further light on the complex genetic 
architecture of GGE. 
 
One limitation of our study is that the cohorts, due to funding restrictions of the individual projects, 
were sequenced at different locations using different technologies. Combining and analysing such 
data in an unbiased way is still a major challenge. To minimize any bias, we used only those 
regions after QC that were available for all samples. An a priori selection bias for the targeted 
genes yielding a false significance can also not be completely ruled out. The careful choice of 
gene-sets was based on biological and published evidence and did not change the selection 
afterwards which should minimize selection bias and associated false-positive findings. 
Furthermore, we used a stringent QC and consistent processing of all datasets, and altogether three 
independent case and control datasets for discovery, validation and replication of results. Neutral 
signals emerging from the synonymous variants across all case-control studies suggest that we 
controlled for any major population structure or other confounding factor. 
 
One of the variants we functionally examined in our study (p.V316I in GABRB2) has been 
identified in the meantime as a de novo mutation in a cohort of severe developmental and epileptic 
encephalopathies using whole genome sequencing of parent-patient trios32. This finding 
corroborates the pathogenicity of this variant. Association of genetic variants with different 
  
phenotypes is well-known as pleiotropy and has also been described in other GABAA receptor 
encoding genes3,24 including large phenotypic variability within one extended pedigree3.  
 
We have also recently characterized the variant p.T336M in GABRA3 – which was detected in our 
discovery cohort (table S8) – as part of another study in which we identified GABRA3 as a new 
epilepsy gene associated with highly heterogeneous epileptic phenotypes including asymptomatic 
variant carriers37. This variant also causes a severe loss-of-function effect but does not co-
segregate in the respective pedigree, so that other factors must contribute to the GGE at least in 
two family members. While co-segregation is a strong indicator for the pathogenicity of genetic 
variants, we have to be aware that GGE is a common disease with complex inheritance. Variants 
in GABAA receptor encoding genes could therefore still contribute to the disease, whereas other 
family members not carrying the respective variants must have other causes of their epilepsy. 
Similarly, copy number variations often do not co-segregate within nuclear families but have been 
replicated as a significant risk factor for GGE38–41. Given the reproducibility of our results, co-
segregation and functional evidence, many but not all of the detected variants may contribute to 
the etiology of GGE in our three cohorts. This disease-relevant contribution may range from a 
major gene effect – as observed in ‘monogenic’ Mendelian epilepsies – to relatively small effect 
sizes in the variant carriers, depending on the amount of the electrophysiological dysfunction and 
other unknown factors, such as the genetic background. Overall, we consider the enrichment of 
GABAA receptor variants in cases vs. controls as a significant risk factor to develop GGE.  
 
Lastly, our results indicate a genetic overlap among rare and common forms of epilepsy, since 
there is increasing evidence that de novo variants in GABAA receptor encoding genes cause severe 
forms of epileptic encephalopathies22–26,37,42 and they re-iterate a central role of GABAergic 
mechanisms in generalized epilepsies3–5,23–25,27–31,43,44. 
Contributions 
HL, RolK, PC, FZ, SM, PN, PM and SG designed the study. FB, SW, PLT, CM MG, SB, PS, HC, 
AS, KE, RB, RolK, RSM, HH, HM, IH, WK, YGW, SW, PdJ, SMS, SS, RN, SF, AC, MSV, 
DKNT, BB, UO, NB, KMK, FR, DKN, FD, LC, AL, RD, JFC, CCW, GA, TS, ELG, BPCK, FZ, 
PC, HL, GJS, PA, BF, MRJ, AGM, BBe, JWS, AA, MMc, GLC, ND, CD, MK, FZi, MNi, and 
the Epicure, EuroEPINOMICS CoGIE and the EpiPGX consortia recruited and phenotyped 
subjects. JvR, RK, AI, AGU recruited, phenotyped and analysed the Rotterdam cohort individuals. 
PM, SG, DRB, SaP, JS, CDK, MT, AP, MI, RGL, SB, CM, HT, JA, KJ, AKR, WJ, DL, ELG, 
JMS, BPCK, AP, AEL, MN, PN, FZ, PC, RolK, and HL performed or supervised genetic studies 
(Sanger or whole exome sequencing, or data analysis), MH, CEN, JK, RR, SC, BT, IDC, CAR, 
SS, SP, MM, SM and HL performed or supervised functional studies, PM, SG, MH, DRB, JS, SW, 
  
and HL wrote the manuscript. Consortia members collected data. All authors revised the 
manuscript. 
Declarations of interests 
HL reports grants from Deutsche Forschungsgemeinschaft (DFG), grants from European 
Commission, other from Foundation no-epilep, grants from Deutsche Gesellschaft für 
Epileptologie (DGfE),  during the conduct of the study; personal fess for consulting, speaking or 
travel support from Bial, Biomarin, Desitin, Eisai, and UCB Pharma,  outside the submitted work; 
he received funding from DFG, BMBF, EU DGfE and the foundation noepilep related in part to 
this work. KMK reports personal fees from UCB Pharma, Novartis Pharma AG, and Eisai, outside 
the submitted work. SP reports other from Praxis Precision Medicine, grants from RogCon, other 
from Pairnomix, outside the submitted work; In addition, SP has a patent U.S. Provisional 
Application 62/450,025 pending. FR reports personal fees and non-financial support from UCB 
Pharma, personal fees from Shire, personal fees from EISAI, personal fees from Desitin 
Arzneimittel, personal fees from Bial, personal fees from cerbomed, GW-Pharma, Bayer Vital, 
Sandoz, University of Munich (LMU), and from Verband der forschenden Arzneimittelindustrie, 
non-financial support from Novartis Japan, grants from European Union, FP7, grants from 
Hessisches Ministerium für Wissenschaft und Kunst (LOEWE-Programme), personal fees from 
University of Munich (LMU), grants from Detlev-Wrobel Fonds for Epilepsy Research, outside 
the submitted work. AA is employed by UCB Pharma SPRL, Belgium, as Associate Director; he 
reports grants from the European Commission, during the conduct of the study; other from UCB 
Pharma, Belgium, outside the submitted work. AGM was awarded grants from GSK, Eisai and 
UCB Pharma, which funded the National Audit of Seizure Management in Hospitals, and the 
European Union during the conduct of the study. JWS reports grants and personal fees from Eisai, 
grants and personal fees from UCB, grants from WHO, grants from NEF, personal fees from from 
Eisai, grants and personal fees from UCB, outside the submitted work;  and Prof Sander's current 
position is endowed by the Epilepsy Society, he is a member of the Editorial Board of the Lancet 
Neurology, and receives research support from the Marvin Weil Epilepsy Research Fund. AC was 
awarded a grant from EISAI and personal fees for speaking from Eisai, outside of the submitted 
work. GJS reports grants from the European Commision (FP7), during the conduct of the study; 
personal fees from UCB Pharma, personal fees from Eisai Ltd., outside the submitted work. CD 
reports grants and personal fees from UCB Pharman, outside the submitted work. AP reports grants 
and personal fees from serving the Pfizer Genetics Scientific Advisory Panel and the FinnGen 
Project, outside the submitted work. RB reports other from Co-Founder of "Theracule", other from 
Co-Foundeer of "Megeno", outside the submitted work. PA reports grants from the EU FP7 
(EpiPGX), during the conduct of the study. PM is Co-Founder of "Megeno", outside the submitted 
work. The other authors declare no competing financial interests. 
 
  
Acknowledgements 
We thank all individuals who participated in this study. The study was supported by the European 
Commission (FP6 project Epicure, LSHM-CT-2006-037315 to HL, FZ, PN, AEL, BPCK, JMS, 
ELG, CM, TS, MM, SS, GA, FR, SF, RN, WK, and FP7 Grant 279062 EpiPGX to SMS, HL, 
GLC, GJS, MRJ, AGM, CD, FZ, WK, JWS, BPCK), by the European Science Foundation 
(EuroEPINOMICS project, grants from national funding agencies: DFG: Le1030/11-1/2 to HL, 
Nu50/8-1 to PN, Sa434/5-1 to TS, He5415/3-1 to IH; FNR: INTER/ESF/10/02/CoGIE to RB; 
Academy of Finland 141549 to AEL; TUBITAK 110S518 to HC.; associated partners without 
funding were: FZ, AP, BPCK, MM, SP, SS), by Research Unit FOR2715 of the DFG and the FNR 
(grants Le1030/16-1, Nu50/11-1, Kr5093/2-1), by the German Society for Epileptology (DGfE: to 
HL, YGW, IH and HM), by the foundation no-epilep (to HL), the Epilepsy Society UK (to JWS, 
SMS), Wellcome Trust (086185/Z/08/Z to IDC), the MRC (MR/J002976/1 to IDC), the Royal 
Society (to SS), and the International Coordination Action (ICA) grant G0E8614N (to SW), by the 
JPND Courage-PD research grant (PM, DRB) and the FNR NCER-PD grant (RB, PM). The work 
was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK 
Department of Health's NIHR Biomedical Research Centres funding scheme. MMc and GLC are 
supported by Science Foundation Ireland, grant 13/CDA/2223. MMc is supported by a Marie-
Curie Individual Fellowship (No. 751761) from the European Commission. This work was partly 
performed at UCLH/UCL, which received a proportion of funding from the Department of Health's 
NIHR Biomedical Research Centres funding scheme (JWS, SMS). The generation and 
management of genomics data for the Rotterdam Study are supported by the Netherlands 
Organisation of Scientific Research NOW Investments (nr. 175.010.2005.011, 911-03-012) and 
the Netherlands Genomics Initiative (NGI)/NOW project nr. 050-060-810 (Netherlands 
Consortium for Healthy Ageing; NCHA). We thank the members of the Genomics Lab and the 
ERGO support team for their help in sampling the data and in creating the database. The Rotterdam 
Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands 
Organization for the Health Research and Development (ZonMw), the Research Institute for 
Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of 
Rotterdam. The authors are grateful to the study participants, the staff of the Rotterdam Study and 
the participating general practitioners and pharmacists. Parts of the computational analysis was 
performed on the high-performance computer system of the University of Luxembourg 
(https://hpc.uni.lu). 
Epicure Consortium 
Merle Harrer, Julian Schubert, Carolien De Kovel, Mohamad Toliat, Anne Polvi, Michele 
Iacomino, Rosa Guerrero-López , Stéphanie Baulac, Carla Marini, Raffaella Rusconi, Benedetta 
  
Terragni, Pasquale Striano, Auli Siren, Hiltrud Muhle, Ingo Helbig, Wolfram Kunz, Yvonne G. 
Weber, Rima Nabbout, Edoardo Ferlazzo, Carlo di Bonaventura, Angela La Neve, Paolo Tinuper, 
Francesca Bisulli, Aglaia Vignoli, Giuseppe Capovilla, Giovanni Crichiutti, Antonio Gambardella, 
Vincenzo Belcastro, Amedeo Bianchi, Silvana Franceschetti, Antonietta Coppola, Maria S. Vari, 
Dorothée Kasteleijn-Nolst Trenité, Betul Baykan, Ugur Ozbek, Nerses Bebek, Karl-Martin Klein, 
Felix Rosenow, Giuliano Avanzini, Stephanie Schorge, Massimo Mantegazza, Thomas Sander, 
Eric LeGuern, Jose M. Serratosa, Bobby P.C. Koeleman, Anna-Elina Lehesjoki, Peter Nürnberg, 
Snezana Maljevic, Federico Zara and Holger Lerche.  
EuroEPINOMICS CoGIE Consortium 
Patrick May, Merle Harrer, Julian Schubert, Felicitas Becker, Stefan Wolking, Cristina Elena 
Niturad, Julia Knaus, Stéphanie Baulac, Holger Thiele, Janine Altmüller, Kamel Jabbari, Ann-
Kathrin Ruppert, Wiktor Jurkowski, Dennis Lal, Pasquale Striano, Hande Caglayan, Destina 
Yalçın, Gulsen Dizdarer, Kezban Arslan, Zuhal Yapici, Demet Kuşcu, Auli Siren, Kate Everett, 
Rikke S. Møller, Helle Hjalgrim, Marina Nikanorova, Hiltrud Muhle, Ingo Helbig, Wolfram Kunz, 
Yvonne Weber, Sarah Weckhuysen, Peter De Jonghe, Sanjay Sisodiya, Rima Nabbout, Rudi 
Balling, Stephanie Schorge, Steven Petrou, Massimo Mantegazza, Thomas Sander, Eric LeGuern, 
Jose M. Serratosa, Bobby P.C. Koeleman, Aarno Palotie, Anna-Elina Lehesjoki, Michael 
Nothnagel, Peter Nürnberg, Snezana Maljevic, Federico Zara, Roland Krause and Holger Lerche. 
EpiPGX Consortium  
Rikke S. Møller, Marina Nikanorova, Chantal Depondt, Michael M. Johnson, Sarah R. Langley, 
Karl M. Klein, Mark McCormack, Norman Delanty, Gianpiero L. Cavalleri, Hiltrud Muhle, 
Mojgansadat Borghei, Joseph Willis, Costin Leu, Kristin Heggeli, Andreja Avbersek, Sanjay M. 
Sisodiya, Josemir W. Sander, Antonio Gambardella, Sarah Weckhuysen, Bianca Berghuis,  
Wolfram S. Kunz, Pasquale Striano, Federico Zara, Anthony G. Marson, Andrea Jorgensen, Pauls 
Auce, Ben Francis, Prashant Srivastava, Graeme J. Sills, Sarah Peter, Roland Krause, Stefan 
Wolking, Yvonne G. Weber, Sarah Rau, Christian Hengsbach, Holger Lerche, Anja C.M. Sonsma, 
Martin Krenn, Fritz Zimprich. 
 
References 
1 Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: 
Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 
512–21. 
2 Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: Genetics of the major 
epilepsy syndromes. Ann Neurol 1998; 43: 435–45. 
3 Wallace RH, Marini C, Petrou S, et al. Mutant GABAA receptor γ2-subunit in childhood 
  
absence epilepsy and febrile seizures. Nat Genet 2001; 28: 49–52. 
4 Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(A) 
receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet 2001; 28: 
46–8. 
5 Cossette P, Liu L, Brisebois K, et al. Mutation of GABRA1 in an autosomal dominant 
form of juvenile myoclonic epilepsy. Nat Genet 2002; 31: 184–9. 
6 Arsov T, Mullen SA, Rogers S, et al. Glucose transporter 1 deficiency in the idiopathic 
generalized epilepsies. Ann Neurol 2012; 72: 807–15. 
7 Striano P, Weber YG, Toliat MR, et al. GLUT1 mutations are a rare cause of familial 
idiopathic generalized epilepsy. Neurology 2012; 78: 557–62. 
8 Klassen T, Davis C, Goldman A, et al. Exome sequencing of ion channel genes reveals 
complex profiles confounding personal risk assessment in epilepsy. Cell 2011; 145: 1036–48. 
9 Heinzen EL, Depondt C, Cavalleri GL, et al. Exome sequencing followed by large-scale 
genotyping fails to identify single rare variants of large effect in idiopathic generalized epilepsy. 
Am J Hum Genet 2012; 91: 293–302. 
10 Epi4K Consortium, Epilepsy Phenome/Genome Project. Ultra-rare genetic variation in 
common epilepsies: a case-control sequencing study. Lancet Neurol 2017; 16: 135–43. 
11 Agostinelli S, Accorsi P, Beccaria F, et al. Clinical dissection of early onset absence 
epilepsy in children and prognostic implications. Epilepsia 2013; 54: 1761–70. 
12 Galizia EC, Myers CT, Leu C, et al. CHD2 variants are a risk factor for photosensitivity 
in epilepsy. Brain 2015; 138: 1198–208. 
13 Hofman A, Brusselle GGO, Darwish Murad S, et al. The Rotterdam Study: 2016 
objectives and design update. Eur J Epidemiol 2015; 30: 661–708. 
14 Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam Study: 2018 update on 
objectives, design and main results. Eur J Epidemiol 2017; 32: 807–50. 
15 UK10K Consortium, Walter K, Min JL, et al. The UK10K project identifies rare variants 
in health and disease. Nature 2015; 526: 82–90. 
16 DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and 
genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491–8. 
17 Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 
60,706 humans. Nature 2016; 536: 285–91. 
18 Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal 
components analysis corrects for stratification in genome-wide association studies. Nat Genet 
2006; 38: 904–9. 
19 Li B, Leal SM. Methods for Detecting Associations with Rare Variants for Common 
Diseases: Application to Analysis of Sequence Data. Am J Hum Genet 2008; 83: 311–21. 
20 Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive 
tool for rare variant association analysis using sequence data. Bioinforma Oxf Engl 2016; 32: 
1423–6. 
21 Lee S, Emond MJ, Bamshad MJ, et al. Optimal Unified Approach for Rare-Variant 
Association Testing with Application to Small-Sample Case-Control Whole-Exome Sequencing 
Studies. Am J Hum Genet 2012; 91: 224–37. 
22 Möhler H. GABAA receptor diversity and pharmacology. Cell Tissue Res 2006; 326: 
505–16. 
23 Johannesen K, Marini C, Pfeffer S, et al. Phenotypic spectrum of GABRA1: From 
generalized epilepsies to severe epileptic encephalopathies. Neurology 2016; 87: 1140–51. 
  
24 Møller RS, Wuttke TV, Helbig I, et al. Mutations in GABRB3: From febrile seizures to 
epileptic encephalopathies. Neurology 2017; 88: 483–92. 
25 Kang J-Q, Macdonald RL. Molecular Pathogenic Basis for GABRG2 Mutations 
Associated With a Spectrum of Epilepsy Syndromes, From Generalized Absence Epilepsy to 
Dravet Syndrome. JAMA Neurol 2016; 73: 1009. 
26 Epi4K Consortium, Epilepsy Phenome/Genome Project. De novo mutations in epileptic 
encephalopathies. Nature 2013; 501: 217–21. 
27 Shen D, Hernandez CC, Shen W, et al. De novo GABRG2 mutations associated with 
epileptic encephalopathies. Brain 2017; 140: 49–67. 
28 Caraiscos VB, Elliott EM, You-Ten KE, et al. Tonic inhibition in mouse hippocampal 
CA1 pyramidal neurons is mediated by 5 subunit-containing -aminobutyric acid type A 
receptors. Proc Natl Acad Sci 2004; 101: 3662–7. 
29 Hedrich UBS, Liautard C, Kirschenbaum D, et al. Impaired Action Potential Initiation in 
GABAergic Interneurons Causes Hyperexcitable Networks in an Epileptic Mouse Model 
Carrying a Human NaV1.1 Mutation. J Neurosci 2014; 34: 14874–89. 
30 Zhang N, Wei W, Mody I, Houser CR. Altered Localization of GABAA Receptor 
Subunits on Dentate Granule Cell Dendrites Influences Tonic and Phasic Inhibition in a Mouse 
Model of Epilepsy. J Neurosci 2007; 27: 7520–31. 
31 Srivastava S, Cohen J, Pevsner J, et al. A novel variant in GABRB2 associated with 
intellectual disability and epilepsy. Am J Med Genet A 2014; 164: 2914–21. 
32 Hamdan FF, Myers CT, Cossette P, et al. High Rate of Recurrent De Novo Mutations in 
Developmental and Epileptic Encephalopathies. Am J Hum Genet 2017; 101: 664–85. 
33 Ishii A, Kang J-Q, Schornak CC, et al. A de novo missense mutation of GABRB2 causes 
early myoclonic encephalopathy. J Med Genet 2017; 54: 202–11. 
34 Lee S, Abecasis GR, Boehnke M, Lin X. Rare-Variant Association Analysis: Study 
Designs and Statistical Tests. Am J Hum Genet 2014; 95: 5–23. 
35 Auer PL, Lettre G. Rare variant association studies: considerations, challenges and 
opportunities. Genome Med 2015; 7: 16. 
36 Bobbili DR, Lal D, May P, et al. Exome-wide analysis of mutational burden in patients 
with typical and atypical Rolandic epilepsy. Eur J Hum Genet EJHG 2018; 26: 258–64. 
37 Niturad CE, Lev D, Kalscheuer VM, et al. Rare GABRA3 variants are associated with 
epileptic seizures, encephalopathy and dysmorphic features. Brain J Neurol 2017; 140: 2879–94. 
38 Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idiopathic 
generalized epilepsy. Nat Genet 2009; 41: 160–2. 
39 Dibbens LM, Mullen S, Helbig I, et al. Familial and sporadic 15q13.3 microdeletions in 
idiopathic generalized epilepsy: precedent for disorders with complex inheritance. Hum Mol 
Genet 2009; 18: 3626–31. 
40 de Kovel CGF, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and 
16p13.11 predispose to idiopathic generalized epilepsies. Brain J Neurol 2010; 133: 23–32. 
41 Mefford HC. CNVs in Epilepsy. Curr Genet Med Rep 2014; 2: 162–7. 
42 Shen D, Hernandez CC, Shen W, et al. De novo GABRG2 mutations associated with 
epileptic encephalopathies. Brain 2017; 140: 49–67. 
43 Lerche H, Shah M, Beck H, Noebels J, Johnston D, Vincent A. Ion channels in genetic 
and acquired forms of epilepsy: Ion channels in epilepsy. J Physiol 2013; 591: 753–64. 
44 Macdonald RL, Kang J-Q, Gallagher MJ. Mutations in GABA A receptor subunits 
associated with genetic epilepsies: GABA A receptor subunits associated with genetic epilepsies. 
  
J Physiol 2010; 588: 1861–9. 
 
Figure legends 
 
Figure 1: Characterization of GABRB2 missense variants associated with GGE  
GABRB2 mutations associated with GGE. (a) Family pedigrees. (b) Schematic representation of 
the E2 subunit of the GABAAR and predicted positions of the R3S and K221R mutations located 
in the N-terminal domain and V316I located in the transmembrane domain 3. (c) Examples of 
GABA-induced currents after 1 mM GABA application for WT, R3S, K221R and V316I 
mutations. (d) Current responses normalized to 1 mM GABA application for WT (n=30), R3S 
(n=24), K221R (n=21) and V316I (n = 16); ***p<0.001, ****p<0.0001, Kruskal Wallis test, with 
Dunn´s comparison test. (e) Dose-response curve for D1E2J2s WT (n=30), R3S (n=14), K221R 
(n=10), V316I (n=7) obtained using application of different GABA concentrations and 
normalization to the maximal GABA response for each cell.  
 
Figure 2: Characterization of GABRA5 missense variants associated with GGE 
GABRA5 mutations associated with GGE. (a) Family pedigrees. (b) Schematic representation of 
the D5 subunit of the GABAAR and predicted positions of the M1I, S238N and E243K mutations 
located in the N-terminal domain and P453L located in the C-terminal domain. (c) Examples of 
GABA-induced currents after application of 1 mM GABA for WT, M1I, S238N, E243K and 
P453L mutations. (d) Normalized current responses to 1 mM GABA application for WT (n=43), 
M1I (n=10), S238N (n=13), E243K (n=14) and P453L (n=11); ****p<0.0001, Kruskal Wallis test, 
with Dunn´s comparison test. (e) Dose-response curve for D1E2J2s WT (n=37), M1I (n=15), 
S238N (n=11), E243K (n=8) and P453L (n=8) obtained after application of different GABA 
concentrations and normalization to the maximal GABA response for each cell.  
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CAE
JME
JAE
JAE CAE
EGTCS
CAE
CoGIE (discovery) 
Gene-set Variant class 
Number 
variants 
Number 
cases 
Number 
controls 
SKAT-O  
P-value 
uncorrected 
SKAT-O 
 P-value 
corrected  
OR Lower CI Upper CI 
Epileptic encephalopathies SYN 284 152 549 0.292299 1 1.25 0.87 1.80 
Excitatory receptors SYN 151 152 549 0.212472 1 1.43 0.97 2.11 
Focal epilepsies SYN 110 152 549 0.416506 1 1.07 0.68 1.66 
GABAergic pathway SYN 444 152 549 0.0628653 0.8172489 1.33 0.92 1.92 
GABA-A receptors SYN 64 152 549 0.574707 1 1.37 0.78 2.40 
Generalized epilepsies SYN 177 152 549 0.237372 1 0.99 0.67 1.47 
Voltage-gated ion channels SYN 471 152 549 0.771146 1 1.19 0.81 1.74 
Epileptic encephalopathies NONSYN 259 152 549 0.528544 1 1.42 0.98 2.07 
Excitatory receptors NONSYN 241 152 549 0.708729 1 1.01 0.69 1.48 
Focal epilepsies NONSYN 142 152 549 0.523553 1 1.42 0.93 2.17 
GABAergic pathway NONSYN 564 152 549 0.442513 1 1.66 1.12 2.46 
GABA-A receptors NONSYN 63 152 549 0.0013633 0.0190862 2.40 1.41 4.10 
Generalized epilepsies NONSYN 194 152 549 0.166314 1 2.17 1.49 3.17 
Voltage-gated ion channels NONSYN 664 152 549 0.601852 1 1.78 1.17 2.70 
EpiPGX (validation) 
GABA-A receptors SYN 99 357 1485 0.587127 0.58712700 0.82 0.54 1.25 
GABA-A receptors NONSYN 107 357 1485 0.00805992 0.01611984 1.46 1.05 2.03 
GABA_panel (replication) 
GABA-A receptors* SYN 86 583 635 0.0613778 0.0613778 0,87 0,6 1,25 
GABA-A receptors* NONSYN 85 583 635 0.0133277 0.0266554 1,46 1,02 2.08 
 
For all cohorts, the corrected and uncorrected SKAT-O P-values for different gene-sets and variant classes are given, together with the number 
of qualifying variants per gene-set as well as the number of cases and controls used for testing. SYN=synonymous variants.  NONSYN=missense 
variants, OR=odds ratio, CI=confidence interval. Enriched gene-sets after applying an FDR threshold of 0.05 are marked in red. OR was calculated 
for only qualifying rare variants (missense or synonymous) over all genes per gene-set. Gene-sets are described in the appendix. *In the 
replication cohort, we used a reduced set of 15 autosomal GABAA receptor genes because of gender QC reasons. 
 
Table 1: Gene-set burden analysis for rare coding variants in three GGE cohorts 
